Who
Badreddin Edris
Director
Company insider
Files Form 4 as: Director, Edgewise Therapeutics; Chief Operating Officer, SpringWorks Therapeutics.
In numbers
- Trades disclosed
- 83
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $17.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Mar 2020
- Last trade
- 5 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,619 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,188 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,619 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,188 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,33913,690 at $0.39 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.0M66,477 at $29.44 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,463 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,477 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,605 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,236 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,690 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | $11K17,236 at $0.64 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K10,463 at $1.93 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,463 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,477 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,605 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,236 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,690 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | $128K66,477 at $1.93 | filing |
| 21 Jan 2026filed 23 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,4007,605 at $0.71 | filing |
News
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock DownEWTX · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Badreddin Edris; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.